Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage from their latest actions.

RDI Initiates
Coverage:

Osiris Therapeutics,
Inc. https://ub.rdinvesting.com/news/?ticker=OSIR

Omeros Corporation https://ub.rdinvesting.com/news/?ticker=OMER

Osiris Therapeutics advanced 19.75% to close at $4.73 on Tuesday. The stock traded between $4.9385 and $4.10 on volume of 305,977 shares traded. The Company was delisted from NASDAQ on March 14th, due to failure to keep the stock exchange up to date with its current financial statements, as the company has previously informed the exchange about material inaccuracies in its books of accounts. Yesterday, the company announced that it has completed the required financials by filing an amended Form 10-K/A for 2014 with the SEC where it has restated product revenue for the year 2014 to $50.8 million, slightly higher than estimated range of restated revenue of $46 million to $50 million, however restated loss for the year 2014 also increased significantly to $10 million or $0.29 a share, higher than previously reported net loss of $1.8 million or $0.05 a share. The new data shows slight Additionally, Osiris anticipates increases in product revenue for 2015 and 2016: Revenue in the range of $89 million to $92 million, up from previously announced range of $85 million to $90 million for year 2015 and revenue in the range of $110 million to $114 million, up from previously announced range of $100 million to $110 million for year 2016. Osiris develops and markets its products in the areas of wound care, orthopedics, and sports medicine. Investors expect the company will begin the process of refiling an application to be reinstated to the NASDAQ.

Access RDI’s Osiris Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=OSIR

Omeros investors saw their company’s stock rise 11.29% to close at $14.10 on Tuesday. The stock traded with significant price swings, ranging from a high of $16.40 to a low of $12.51 on volume of 3.67 million shares traded. The company develops and commercializes therapies targeting inflammation, coagulopathies, and disorders of the central nervous system. On March 1st of this year, Omeros announced positive data results from its ongoing Phase II clinical trial evaluating its lead candidate OMS721 drug. The positive results have brought offers for the company to present its results from the Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome on April 22nd to the World Congress of Nephrology. Additionally, the company has been invited to present the test results at the annual meeting of the European Society for Blood and Marrow. Transplantation. Omeros has witnessed significant revenue growth in the fourth quarter and full year of 2016 and has reported loss of $19.6 million or $0.45 a share and $66.75 million or $1.65 a share, for the fourth quarter and full year of 2016 respectively. Company had $45.3 million in cash assets as on December 31st, 2016.

Access RDI’s Omeros Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=OMER

Our Actionable Research on Osiris Therapeutics, Inc. (OTC PINK: OSIR) and Omeros Corporation (NASDAQ: OMER) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458450